Repurposing medicinal compounds for blood cancer treatment

Bronagh McCabe, Fabio Liberante, Ken I Mills

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)
274 Downloads (Pure)


Drug development is being continuously scrutinised for its lack of productivity. Novel drug development is associated with high costs, high failure rates and lengthy development process. These downfalls combined with a huge demand in blood cancer for new therapeutic treatments have led many to consider the method of drug repurposing. Finding new therapeutic indications for already established drug substances is known as redirecting, repositioning, reprofiling, or repurposing of drugs. Off-patent and on-patent drugs can be screened for additional targets and new indications thus bringing them to clinical trials at a faster pace. This approach offers smaller research groups, such as those that are academic based, into the drug development industry. Drug repurposing can make use of previously published data concerning dosage, toxicology and mechanism of activity.

Original languageEnglish
Pages (from-to)1267-1276
Number of pages10
JournalAnnals of Hematology
Issue number8
Early online date07 Jun 2015
Publication statusPublished - Aug 2015


Dive into the research topics of 'Repurposing medicinal compounds for blood cancer treatment'. Together they form a unique fingerprint.

Cite this